TScan Therapeutics (TCRX) Short term Debt (2023 - 2026)

TScan Therapeutics (TCRX) posted quarterly Short term Debt of $10.3 million for Q2 2024, up 52.07% quarter-over-quarter from $6.8 million in Q1 2024.

TScan Therapeutics (TCRX) Short term Debt (2023 - 2026) Analysis & Trends

TScan Therapeutics (TCRX) has reported Short term Debt for 2 consecutive years, with $10.3 million the latest figure, recorded in Q2 2024.

In Q2 2024, Short term Debt changed N/A year-over-year to $10.3 million; the TTM figure through Jun 2024 stood at $10.3 million (changed N/A YoY), while the FY2023 annual figure was $3.3 million, changed N/A from the prior year.
Short term Debt advanced to $10.3 million in Q2 2024 per TCRX's latest filing, from $6.8 million in the prior quarter.
Across five years, Short term Debt topped out at $10.3 million in Q2 2024 and bottomed at $1.1 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	TScan Therapeutics	100.62 Mn	100.62 Mn	-

Download Data